Pfizer reports top end of 2024 guidance Read in browser

Thank you for reading, dupa dupackia! basic Subscription UPGRADE

M Tue W Th F 4 February, 2025

The early-stage R&D landscape is evolving faster than ever. But which approaches are delivering real results? Find out — join us for Drug Discovery Day.

SPOTLIGHT In Focus Drugmakers seize on biomarkers to test the FDA's rare disease shift

news Regeneron will start delivering quarterly dividends 37 years into its existence Merck temporarily pauses Gardasil shipments to China following sales slowdown Pfizer reports top end of 2024 guidance Flagship spinout Omega is days away from bankruptcy, it says in filing Astellas shakes up management despite impressive nine-month earnings

Feb 04 12:00pm ET New data: Optimizing breast cancer care and drug development with molecular residual disease testing sponsored by Natera

ENDPOINTS PHARMA Biogen’s revised research strategy is to avoid becoming obsolete, top exec says Senate Democrats say RFK Jr.'s divestment plans are 'plainly inadequate' ahead of Tuesday vote US biosimilar 'void' spells trouble as biologic patent expirations loom, IQVIA report says Thermo Fisher to lay off 300 workers at two viral vector factories   Charles River to shut down North Carolina pathology facility, says it's not a 'strategic fit' Gene-edited pig kidneys to be tested in more humans soon, two companies say

Catch up on all of the sessions from Endpoints at #JPM25, including conversations with former FDA Commissioner Scott Gottlieb and Nobel laureate Jennifer Doudna — visit our on-demand hub to watch now.

in case you missed it 1. Updated: Drug prices likely to soar due to Trump tariffs, pharma bodies warn 2. Exclusive: German biotech declares Phase 2 win for non-opioid drug for neuropathic pain 3. Irish startup reports mid-stage victory for short-acting psychedelic drug in depression 4. Sionna seeks $135M IPO to fuel tests of cystic fibrosis drug candidates 5. Australian biotech AdvanCell nabs $112M Series C for radiopharmaceuticals 6. Pfizer says new colorectal cancer data could support full approval of Braftovi 7. J&J’s Rybrevant gets CHMP backing weeks after FDA rejection 8. Marco Rubio Wants USAID to Undergo Overhaul, Backs Off Full Shutdown